Angiotensin-II-receptor inhibitors in pregnancy.
Chung
N A
NA
Lip
G Y
GY
Beevers
M
M
Beevers
D G
DG
D000014:Abnormalities, Drug-Induced / Q000209:etiology / Q000517:prevention & control*; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First; D011295:Prenatal Care; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D013777:Tetrazoles / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors; D014633:Valine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D000068756:Valsartan
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine